Related Experiment Video
Updated: Mar 1, 2026
Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
DHRS9 Is a Stable Marker of Human Regulatory Macrophages
Paloma Riquelme1, Giada Amodio, Camila Macedo
11 Department of Surgery, University Hospital Regensburg, Regensburg, Germany. 2 San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Division of Regenerative Medicine, Stem Cells and Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy. 3 Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA. 4 INSERM UMR1064, Center for Research in Transplantation and Immunology, Nantes, France. 5 CHU de Nantes, Institut de Transplantation Urologie Nephrologie (ITUN), Nantes, France. 6 Université de Nantes, Nantes, France. 7 Division of Surgical Oncology, University of Pittsburgh, Hillman Cancer Center, Pittsburgh, PA. 8 Institute of Pathology, University Hospital Regensburg, Regensburg, Germany. 9 Department of Transfusion Medicine, University Hospital Regensburg, Regensburg, Germany. 10 Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. 11 FinVector Vision Therapies Oy, Microkatu 1S, Kuopio, Finland. 12 Institute for Applied Cell Therapy, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Background:
The human regulatory macrophage (Mreg) has emerged as a promising cell type for use as a cell-based adjunct immunosuppressive therapy in solid organ transplant recipients. In this brief report, dehydrogenase/reductase 9 (DHRS9) is identified as a robust marker of human Mregs.
Methods:
The cognate antigen of a mouse monoclonal antibody raised against human Mregs was identified as DHRS9 by immunoprecipitation and MALDI-MS sequencing. Expression of DHRS9 within a panel of monocyte-derived macrophages was investigated by quantitative PCR, immunoblotting and flow cytometry.
Results:
DHRS9 expression discriminated human Mregs from a panel of in vitro derived macrophages in other polarisation states. Likewise, DHRS9 expression distinguished Mregs from a variety of human monocyte-derived tolerogenic antigen-presenting cells in current development as cell-based immunotherapies, including Tol-DC, Rapa-DC, DC-10, and PGE2-induced myeloid-derived suppressor cells. A subpopulation of DHRS9-expressing human splenic macrophages was identified by immunohistochemistry. Expression of DHRS9 was acquired gradually during in vitro development of human Mregs from CD14 monocytes and was further enhanced by IFN-γ treatment on day 6 of culture. Stimulating Mregs with 100 ng/mL lipopolysaccharide for 24 hours did not extinguish DHRS9 expression. Dhrs9 was not an informative marker of mouse Mregs.
Conclusion:
DHRS9 is a specific and stable marker of human Mregs.
More Related Videos
06:22Isolation of Viable Adipocytes and Stromal Vascular Fraction from Human Visceral Adipose Tissue Suitable for RNA Analysis and Macrophage Phenotyping
Published on: October 27, 2020
08:05Production and Characterization of Human Macrophages from Pluripotent Stem Cells
Published on: April 16, 2020